Evidence map›Paper›PMID 35563157›Full record

ArticleInternational journal of molecular sciences2022

HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs.

Zsófia Ilona Szojka, Sara Karlson, Emil Johansson, Gülşen Özkaya Şahin, Marianne Jansson

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zsófia Ilona SzojkaDepartment of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.ORCID 0000-0002-1252-6929
Sara KarlsonDepartment of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
Emil JohanssonDepartment of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
Gülşen Özkaya ŞahinDepartment of Translational Medicine, Lund University, 205 02 Malmö, Sweden.
Marianne JanssonDepartment of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
Lund University · SE

Funding

Swedish Research Council 2016-02285Swedish Research Council 2019-01439The Swedish Fund for Research without Animal Experiments F2021-0010The Swedish Fund for Research without Animal Experiments N2019-0009Wenner-Gren Foundations UPD2021-0173
6 · The paper itself

Abstract

HIV-2, compared to HIV-1, elicits potent and broadly neutralizing antibodies, and uses a broad range of co-receptors. However, both sensitivity to neutralization and breadth of co-receptor use varies between HIV-2 isolates, and the molecular background is still not fully understood. Thus, in the current study, we have deciphered relationships between HIV-2 neutralization sensitivity, co-receptor use and viral envelope glycoprotein (Env) molecular motifs. A panel of primary HIV-2 isolates, with predefined use of co-receptors, was assessed for neutralization sensitivity using a set of HIV-2 Env-directed monoclonal antibodies and co-receptor indicator cell lines. Neutralization sensitivity of the isolates was analysed in relation target cell co-receptor expression, in addition to amino acid motifs and predicted structures of Env regions. Results showed that HIV-2 isolates were more resistant to neutralizing antibodies when entering target cells via the alternative co-receptor GPR15, as compared to CCR5. A similar pattern was noted for isolates using the alternative co-receptor CXCR6. Sensitivity to neutralizing antibodies appeared also to be linked to specific Env motifs in V1/V2 and C3 regions. Our findings suggest that HIV-2 sensitivity to neutralization depends both on which co-receptor is used for cell entry and on specific Env motifs. This study highlights the multifactorial mechanisms behind HIV-2 neutralization sensitivity.

Indexed as

HIV-1HIV InfectionsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV-2HIV AntibodiesHIV Envelope Protein gp120HumansReceptors, G-Protein-CoupledReceptors, PeptideAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusGPR15 protein, humanHIV AntibodiesHIV Envelope Protein gp120Receptors, G-Protein-CoupledReceptors, PeptideEnv motifsHIV-2neutralization sensitivitytarget cell co-receptors

Identifiers

PMID35563157
PMCPMC9101540
OpenAlexW4224942091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.